Dupixent CTCL MDL 3180: What the Transfer Order Means for Patients
What patients and families should know after Dupixent CTCL claims were centralized in MDL No. 3180 in New Jersey.
-
-
Dupixent and CTCL: the new MDL is here, but the paperwork still matters most
A plain-English July 2026 update on Dupixent CTCL MDL 3180, what the JPML order says, and which records families should save now.
-
AFFF (Aqueous Film Forming Foam) | Bard Powerport | Depo Provera | Dupixent | Hair Relaxer | Nec Baby Formula | Paraquat | Roundup | Spinal Cord Stimulator | Talcum Powder | Tavneos
Mass Tort Litigation Update: July 2026
Mid-2026 is one of the busiest stretches in recent mass tort history: two new MDLs formed in a single week in June, the Supreme Court reshaped the Roundup litigation, and the FDA moved to withdraw an approved drug from the market. Here is where the major dockets stand as of July 7, 2026. New MDLs:…
-
Dupixent lawsuit update: CTCL claims and the records families should keep
What families should know about Dupixent lawsuit reviews involving CTCL, recall questions, and the records that help establish the timeline.
